Dipro 10 mg (Escitalopram Oxalate)

Adult dosage

The safety of doses exceeding 20 mg per day has not been established. This medication is administered once daily, in the morning or evening, regardless of meals. Major depressive disorder: The usual dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. If the dose is to be increased to 20 mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are needed for antidepressant effects to become apparent. Even after symptoms have resolved, drug treatment for at least 6 months is required to ensure the treatment effect. Panic disorder with or without agoraphobia: The recommended initial dose is 5 mg per day for 1 week, followed by an increase to 10 mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. The maximum effect occurs after approximately 3 months. The safety and efficacy of long-term administration of this medication for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reevaluate each patient to determine the need for continued treatment. Social anxiety disorder: The usual dose is 10 mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5 mg per day or increased to a maximum of 20 mg per day. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure the treatment effect. Long-term treatment in patients who respond has been studied for 6 months and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be reevaluated regularly. Generalized anxiety disorder: The initial dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day after at least 1 week of treatment. A long-term study was conducted in patients who responded to 12 weeks of open-label treatment, in which 20 mg per day was administered for at least 6 months. The physician should regularly reevaluate the usefulness of long-term treatment with this medication for each patient. Obsessive-compulsive disorder: The usual dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. A long-term study was conducted in patients who responded to 16 weeks of open-label treatment, in which 10 mg or 20 mg per day was administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition; treatment should be continued for a sufficient period to ensure recovery from symptoms. During long-term use of this medication, the usefulness of treatment and the dose should be regularly reevaluated for each patient. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30㎖/min). Patients with hepatic impairment: An initial dose of 5 mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10 mg per day. Discontinuation: When discontinuing this medication, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. Switching from MAO inhibitors for the treatment of psychiatric disorders: When discontinuing an MAO inhibitor used for the treatment of psychiatric disorders and starting treatment with this medication, an interval of at least 14 days should be allowed. Conversely, when starting an MAO inhibitor for the treatment of psychiatric disorders, at least 14 days must have elapsed after discontinuing this medication. Other MAO inhibitors, such as linezolid or methylene blue: Patients receiving linezolid or intravenous methylene blue should not start this medication because of the increased risk of serotonin syndrome. For patients who require more urgent treatment for a psychiatric condition, including hospitalization and other interventional procedures, treatment should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medication. If no alternative to linezolid or intravenous methylene blue is available and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, this medication may be discontinued immediately and linezolid or intravenous methylene blue administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after starting linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medication may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risks associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or with intravenous doses of this medication of 1mg/kg or less are unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is used to treat psychiatric disorders such as major depression, and there is an increased risk of suicidal thoughts or behaviors, especially in children, adolescents, and young adults, hence caution is necessary. This medication must not be used if you have an allergy to any of its components or if you are currently taking certain medications, especially MAO inhibitors. Patients with glaucoma or a history of glaucoma should use this medication cautiously as it may dilate pupils and increase intraocular pressure. During the first 1-2 weeks of treatment, side effects such as anxiety, insomnia, dizziness, nausea, and headaches are common, and they tend to decrease over time. This medication may affect heart rate, so individuals with heart disease or a QT interval prolongation should consult a doctor before taking it. During treatment, it is essential to monitor for any worsening of depressive symptoms or unusual behavioral changes such as suicidality or aggression, and family members or caregivers should also be vigilant. Abrupt discontinuation of this medication can induce withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so it should always be tapered gradually under a doctor's guidance. This medication may affect the newborn if taken during pregnancy, especially in the later stages, so women who are pregnant or planning to become pregnant should consult their doctor. Breastfeeding women should consider stopping breastfeeding or avoiding this medication, as it can be transmitted through breast milk. This medication can interact with other drugs, so anyone taking other medications should inform their physician or pharmacist. Caution is required when driving or operating machinery as this medication may affect mental or physical performance. Special care is needed for children and the elderly, and elderly patients are recommended to start with a lower dose than usual. The safety and efficacy of this medication have not been established in children and adolescents, so its use is not recommended.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, nervousness, panic attacks, confusion, aggression, depersonalization, hallucinations, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbances, tremors, taste disorders, sleep disorders, syncope, serotonin syndrome, dyskinesia, movement disorders, seizures, psychomotor agitation, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, QT interval prolongation, polymorphic ventricular tachycardia, orthostatic hypotension, sinusitis, yawning, nosebleeds, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorders, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, fatigue, fever, edema, headache, dry mouth, abdominal pain, dyspepsia, enteritis, sensory disturbances, cough, asthma, dyspnea, fractures, palpitations, hypertension, paralysis, extrapyramidal disorders, migraine, hallucinations, asthma, dyspnea, chest pain, tremors, dry mouth, frequency of urination, sedation, heartburn, anxiety, visual hallucinations, retrograde anxiety, epileptic seizures, mania, suicidal impulses, hostility, aggressiveness, anger, impulsivity, akathisia, withdrawal symptoms, dizziness, sleep disorders, anxiety, tremors, confusion, sweating, diarrhea, emotional instability, hypersensitivity, visual impairment, QT interval prolongation, persistent sexual dysfunction

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. It is important to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 200 tablets/bottle